Medical device firm SINOMED has collaborated with the National University of Ireland Galway (NUI Galway) to evaluate a non-invasive assessment method for stenting.
The partnership will carry out a PIONEER IV clinical trial for a new stenting assessment method.
The study will use the newly patented HT Supreme healing-targeted drug-eluting stent (DES), which is believed to hold the potential to efficiently treat patients with heart disease.
Under the trial, SINOMED and NUI Galway will recruit up to 2,540 patients suffering from any type of coronary heart disease, including acute heart attack, chronic complaints or vessel narrowing.
SINOMED stated that patients eligible will undergo a non-invasive physiological vessel selection process to which vessel needs stenting.
The HT Supreme DES will be used for all the recruited patients, which need to take one month dual-antiplatelet therapy after stenting.
SINOMED chairman and CEO Dr Jianhua Sun said: “We are honoured to be working with the prestigious thought leaders at NUI Galway in searching for a better and safer strategy for treating patients.
“We believe that our HT Supreme, coupled with an optimal treatment strategy can make a big impact in bringing benefit to patients.”
The study, which is sponsored by NUI Galway, will be regulated by the University’s CORRIB Research Centre for Advanced Imaging and Core Laboratory.
It will be led by interventional medicine and innovation professor Patrick Serruys and Science Foundation Ireland interventional professor William Wijns.
NUI Galway’s College of Medicine, Nursing and Health Sciences Dean professor Timothy O’Brien said: “Leading this research from Galway is consistent with the University strategy to be a global leader in cardiovascular research and innovation and compliments the presence in the University of CURAM, the SFI Research Centre for Medical Devices.
“We are particularly happy to partner with SINOMED on this project which aligns with the University’s Global Galway Project.”
